Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia

Actas Espanolas de Psiquiatria

Volumn 35, Issue 4, 2007, Pages 249-252

  Morera, A L ^a   Henry, M ^b   Garcia Hernandez A ^c   Fernandez Lopez L ^b  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^c NONE

Author keywords

Acute phase proteins; Biological markers; Negative symptoms; Positive symptoms; Psychopathology; Schizophrenia

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER;

ADULT; AFFECT; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; MALE; METABOLISM; PARANOID SCHIZOPHRENIA;

ACUTE-PHASE PROTEINS; ADULT; AFFECT; BIOLOGICAL MARKERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; SCHIZOPHRENIA, PARANOID;

EID: 34547336750     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Wyatt RJ, Kirch DG, de Lisi LE. Schizophrenia: Biochemical, endocrine, and immunological studies. In: Kaplan H, Sadock B, editors. Comprehensive Textbook of Psychiatry, fifth ed. Baltimore: Williams and Wilkins, 1989; p. 717-32.
2. Tamam L, Yerdelen D, Ozpoyraz N. Psychosis associated with interferon alfa therapy for chronic hepatitis B. Ann Pharmacother 2003;37:384-7.
3. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994;89:346-51.
4. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48.
5. Abood LG, Gibbs FA, Gibbs E. Comparative study of blood ceruloplasmin in schizophrenia and other disorders. AMA Arch Neurol Psychiatry 1957;77:643-5.
6. Giner J, Morell M, Osorio C. Serum levels of ceruloplasmin as an index of the clinical evolution in schizophrenic patients. Rev Esp Fisiol 1972;28:39-41.
7. Mora F, Quesada T, Pena J, Osorio C. Ceruloplasmine in schizophrenic and in epileptic patients. Rev Esp Fisiol 1976;32:37-9.
8. Alias AG, Vijayan N, Nair DS, Sukumaran M. Serum ceruloplasmin in schizophrenia: significant increase in acute cases especially in catatonia. Biol Psychiatry 1972;4:231-8.
9. Peralta MV, Cuesta-Zorita MJ. Validation of positive and negative symptom scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1994;22:171-7.
10. Hanel HK, Persson J, Rahbek J. Alterations in various serum protein and serum enzyme levels during treatment with sequence-type oral contraceptives. Ugeskr Laeger 1971;133:487-9.
11. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ 1980;280:66-8.
12. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull 1990;16:537-45.
13. Cuesta MJ, Peralta V. Integrating psychopathological dimensions in functional psychoses: a hierarchical approach. Schizophr Res 2001;52:215-29.
14. Peralta V, Cuesta MJ. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res 1994;53:31-40.
15. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 1994;151:351-6.
16. Puzynski S, Kalinowski A. Investigations of some physio-biochemical properties of ceruloplasmin in schizophrenics and in normal subjects. Nature 1966;212:399-400.
17. Puzynski S. Investigations on ceruloplasmin in chronic schizophrenia. Pol Med J 1966;5:1484-91
18. Bock E, Weeke B, Rafaelsen OJ. Serum proteins in acutely psychotic patients. J Psychiatr Res 1971;9:1-9.
19. Domino EF, Krause RR, Thiessen MM, Batsakis JG. Blood protein fraction comparisons of normal and schizophrenic patients. Arch Gen Psychiatry 1975;32:717-21.
20. Seal US, Eist H. Elevation of serum protein-bound carbohydrates and haptoglobin in schizophrenia. Clin Chem 1966;12:709-16.
21. Spivak B, Radwan M, Elimelech D, Baruch Y, Avidan G, Tyano S. A study of the complement system in psychiatric patients. Biol Psychiatry 1989;26:640-2.
22. Spivak B, Radwan M, Brandon J, Baruch Y, Stawski M, Tyano S et al. Reduced total complement haemolytic activity in schizophrenic patients. Psychol Med 1993;23:315-8.
23. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997;66:1-11.
24. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029-34.
25. Wachowicz B, Krajewski T, Zbikowska H. Protective effect of ceruloplasmin against lipid peroxidation in blood platelets. Acta Biochim Pol 1990;37:261-6.
26. Dumoulin MJ, Chahine R, Atanasiu R, Nadeau R, Mateescu MA. Comparative antioxidant and cardioprotective effects of ceruloplasmin, superoxide dismutase and albumin. Arzneimittelforschung 1996;46:855-61.
27. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998;32:1-8.
28. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001;6: 66-73.
29. Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996;55: 33-43.
30. Sirota P, Gavrieli R, Wolach B. Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity. Psychiatry Res 2003;121:123-32.